AzTrials
AzTrials

Thyroid CancerNCT02347683

Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy

An observational study of Thyroid Cancer, run by University of Nebraska at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks. Hypothesis - Post -op Tg nadirs at 6-8 weeks . Read more about this study

Who is it for?
Ages 19 years and olderHealthy volunteers can take part
Conditions the study is for
Thyroid Cancer
How many people
50 participants
Where
1 siteUnited States
Study dates
1 Jan 2015to 1 Feb 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.

Who may be able to join

  • All patients already planning to undergo total /near total thyroidectomy for reasons unrelated to this study.
  • Age 19 or older

Who cannot join

  • Children < 19 years
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

Other trials in United States

About this study

The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks.

Hypothesis - Post -op Tg nadirs at 6-8 weeks .

Read more

Primary Objective -Determine optimal timing of post thyroidectomy Tg nadir, so to determine the most accurate time to check post operatively.

Secondary Outcome - Determine factors that will affect Tg levels post operatively.

All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.

Measure Tg , Tg Ab and TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, and 3 month in patients with pathology confirmed benign disease.

Measure Tg , Tg Ab , TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, 3 month, 6 month, and 12 month in patients with thyroid cancer.

Read the detailed description

Thyroid cancer, the most common endocrine tumor, constitutes 3.8% of all cancers. 62,980 new cases were estimated in the U.S. in 20141, an increasing trend from the 37,200 new cases in 20092. 90% of all thyroid cancers are differentiated thyroid carcinomas (DTC), which include both papillary and follicular thyroid carcinoma3.

Management of DTC involves a total thyroidectomy, with possible central and lateral neck dissection if there are clinical lymph node involvement, except for low-risk lesions that are unifocal, intrathyroidal, node-negative and measuring less than 1 cm in size. Radioactive iodine ablation of any remnant thyroid tissue may follow a total thyroidectomy depending on the risk stratification of the patient3. As for any cancer, management of thyroid cancer involves long-term surveillance for early detection of disease recurrence3.

According to the ATA guidelines, postoperative surveillance includes regular (every 6 to 12 months) clinical evaluation for tumor recurrence, evaluation with neck ultrasound and serum Thyroglobulin (Tg) levels while on levothyroxine replacement3. Serum Tg has become a very useful and well-acknowledged marker in patients with thyroid cancer post thyroidectomy for disease persistence, metastasis or recurrence.

Thyroglobulin is a 660 kDa dimeric glycoprotein that is exclusively produced and stored by thyroid follicular cells in benign conditions, but also by well-differentiated thyroid cancer cells4. A total thyroidectomy for higher risk patients is thus not only is important to provide definitive treatment and decrease risk of recurrence, but also allows for long term follow-up with Tg levels.

One study has reported Tg is eliminated through the liver and its half-life following total thyroidectomy has been reported to be about 65.2 hours. The Tg level was noted to decrease to less than 5-10 ng/ml 25 days after thyroidectomy, or after 7 to 10 half-lives in 11 patient samples5. Detection of Tg following the total thyroidectomy during long-term surveillance would therefore suggest persistent thyroid tissue.

Despite the determined half-life of Tg, in a retrospective study with 36 patients with low-risk papillary thyroid carcinoma, the unstimulated Tg level fell to < 0.5 ng/ml after 6 months postoperatively in only 61%, and after 2 years postoperatively in 100% of the patients6. No prospective studies have yet determined the nadir of the Tg level post thyroidectomy. In our personal clinical experience, unstimulated serum Tg levels may be found undetectable 6 to 12 weeks following a total thyroidectomy.

The sensitivity, specificity, positive predictive value and negative predictive value of unstimulated (normal or low TSH ) serum Tg in assessing completeness of thyroidectomy (< 0.5 ng/ml) have been reported to be 70%, 100%, 100% and 92% respectively6. Obtaining a basal unstimulated serum Tg level post thyroidectomy not only determines the completeness of the total thyroidectomy7, but also provides a basal level for future comparison during long-term surveillance. The high negative predictive value allows for the identification of patients less likely to have disease recurrence and provide less aggressive and more cost effective management strategies3.

The optimal time to obtain an unstimulated serum Tg level has not yet been determined. Obtaining the Tg level too early following the total thyroidectomy may result in a misleadingly significant Tg level and erroneously suggest residual disease, thereby leading to unnecessary further investigation and more aggressive management strategies. NCCN guidelines suggest to check anywhere between 2-12 weeks in patients with thyroid cancer 8

Radioactive iodine ablation of remnant thyroid tissue may potentially be avoided with a postsurgical stimulated Tg level of < 1ng/ml in low risk, well-differentiated thyroid cancer9. This practice is not yet approved by the American Thyroid Association, and is less likely to be feasible with no concensus on the timing of the Tg measurement.

The objective of this study is therefore to find the nadir of the unstimulated serum Tg level following total thyroidectomy, and therefore the optimal time for Tg measurement in postoperative surveillance.

Conditions
Thyroid Cancer
Medical subject headings
Thyroid Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02347683
Study groupRoleWhat they receive
Benign pathologyWe will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
Malignant pathologyWe will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Optimal timing of post thyroidectomy thyroglobulin (Tg) nadir

    Determine optimal timing of post thyroidectomy thyroglobulin (Tg) nadir, so to determine the most accurate time to check post operatively.

    Measured: within a year

Secondary outcomes (1)
  1. Factors affecting thyroglobulin (Tg) levels post operatively

    Determine factors that will affect thyroglobulin (Tg) levels post operatively

    Measured: within a year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2015 (estimated)
  2. Study start1 Jan 2015
  3. Primary completion1 Feb 2016
  4. Study completion1 Feb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02347683
Sponsor's protocol ID
0594-14-FB
Status last verified
Aug 2023
First submitted
21 Jan 2015
Last updated
5 Sep 2023
Results posted
No
Data monitoring committee
No

Publications

  • Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum Thyroglobulin: Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. Int J Endocrinol. 2019 Feb 20;2019:1384651. doi: 10.1155/2019/1384651. eCollection 2019.

    PubMed 30915112

Questions about this trial

What is this clinical trial studying?

An observational study of Thyroid Cancer, run by University of Nebraska at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Optimal timing of post thyroidectomy thyroglobulin (Tg) nadir (time frame: within a year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02347683, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in